Estrella Immunopharma, Inc. financial data

Symbol
ESLA, ESLAW on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
5858 Horton Street, Suite 370, Emeryville, CA
Fiscal year end
June 30
Former names
TradeUP Acquisition Corp. (to 9/20/2023)
Latest financial report
10-K - Q2 2024 - Sep 27, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 23.8 % -95.6%
Debt-to-equity 56.5 %
Return On Equity -91.7 % -184%
Return On Assets -58.6 % -18.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 36.2M shares
Common Stock, Shares, Outstanding 36.6M shares +3643%
Entity Public Float 40.3M USD
Common Stock, Value, Issued 3.66K USD +3636%
Weighted Average Number of Shares Outstanding, Basic 27.1M shares +8765%
Weighted Average Number of Shares Outstanding, Diluted 27.1M shares +8765%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 4.11M USD -60.7%
General and Administrative Expense 3.2M USD +383%
Operating Income (Loss) -7.31M USD +14.5%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -513K USD +31%
Income Tax Expense (Benefit) 121K USD
Net Income (Loss) Attributable to Parent -7.31M USD +13.6%
Earnings Per Share, Basic -0.27 USD/shares +99.3%
Earnings Per Share, Diluted -0.27 USD/shares +99.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 4.17M USD +68%
Accounts Receivable, after Allowance for Credit Loss, Current 273K USD
Assets, Current 4.45M USD +61.8%
Operating Lease, Right-of-Use Asset 0 USD
Assets 4.45M USD +47.1%
Accrued Liabilities, Current 167K USD
Liabilities, Current 181K USD -98.1%
Deferred Income Tax Liabilities, Net 8.37K USD
Other Liabilities, Noncurrent 12.7K USD
Liabilities 181K USD -98.2%
Retained Earnings (Accumulated Deficit) -19.5M USD -60%
Stockholders' Equity Attributable to Parent 4.27M USD
Liabilities and Equity 4.45M USD +47.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -275K USD +75%
Net Cash Provided by (Used in) Financing Activities 20M USD
Net Cash Provided by (Used in) Investing Activities -112K USD
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 36.6M shares +3643%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -11.4K USD +92.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 4.17M USD +68%
Deferred Tax Assets, Valuation Allowance 4.48M USD +75%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 4.48M USD +75%
Deferred Income Tax Expense (Benefit) -21.7K USD
Deferred Tax Assets, Operating Loss Carryforwards 1.84M USD +418%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 24.1M USD
Preferred Stock, Shares Outstanding 0 shares
Current State and Local Tax Expense (Benefit) 0 USD
Current Federal Tax Expense (Benefit) 113K USD
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 102K USD
Deferred State and Local Income Tax Expense (Benefit) 0 USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%